MCM2 antibody | CRCT2.1
Mouse anti Human MCM2 antibody, clone CRCT2.1 has been used successfully for the detection of human MCM2 in ovarian adenocarcinoma by immunohistochemistry on formalin fixed, paraffin embedded tissues (Gakiopoulou et al. 2007).
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide
- Carrier Free
- Bacterially expressed human Mcm2.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunised CBA/c F1 mice were fused with cells of the mouse SP-2/0 myeloma cell line.
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- Entrez Gene
- GO Terms
- GO:0000075 cell cycle checkpoint
- GO:0000082 G1/S transition of mitotic cell cycle
- GO:0000084 S phase of mitotic cell cycle
- GO:0005515 protein binding
- GO:0000216 M/G1 transition of mitotic cell cycle
- GO:0000785 chromatin
- GO:0046872 metal ion binding
- GO:0005524 ATP binding
- GO:0005654 nucleoplasm
- GO:0006270 DNA-dependent DNA replication initiation
- GO:0006271 DNA strand elongation involved in DNA replication
- GO:0006350 transcription
- GO:0045449 regulation of transcription
- For research purposes only
Applications of MCM2 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Paraffin 1||1/200|
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
- Histology Positive Control Tissue
- Tonsil, any tissue with high proliferative index
Secondary Antibodies Available
Product Specific References
References for MCM2 antibody
Gakiopoulou, H. et al. (2007) Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications.
Br J Cancer. 97:1124-34.
Korkolopoulou, P. et al. (2005) Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Hum Pathol. 36: 899-907.
Giaginis, C. et al. (2009) Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.
Dig Dis Sci. 54: 282-91.
Polo, S.E. et al. (2010) Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours.
Histopathology. 57: 716-24.
FitzGerald, J. et al. (2014) A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response.
PLoS One. 9: e98891.
Almouzni, G. et al. (2011) Proliferation markers in clinical practice and their use for breast cancer prognosis or diagnosis.
U.S. Patent Application: US 20110003706 A1
Montes de Oca, R. et al. (2015) The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
Mol Oncol. 9 (3): 657-74.
Wu, K.Z. et al. (2016) DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach.
Nucleic Acids Res. 44 (18): 8786-8798.